SURMOUNT Trials: Tirzepatide Weight Loss Data
Tirzepatide
22.5% weight loss
The highest dose of tirzepatide produced 22.5% mean body weight reduction versus 2.4% for placebo over 72 weeks in the landmark SURMOUNT-1 trial.
Jastreboff et al., NEJM, 2022
Jastreboff et al., NEJM, 2022
View as imageThe SURMOUNT program is the clinical trial series that earned tirzepatide its FDA approval for weight management under the brand name Zepbound. Five trials, enrolling thousands of participants across different populations, established tirzepatide as the most effective single-agent weight loss peptide drug tested to date. The numbers are striking: up to 22.5% body weight reduction at the highest dose, 57% of participants losing 20% or more of their body weight, and a 94% reduction in progression from prediabetes to type 2 diabetes over three years.[1][6] This article breaks down each SURMOUNT trial with specific numbers, what each one tested, and what the data actually shows. For how tirzepatide's dual GIP/GLP-1 mechanism produces these results, see How Tirzepatide's Dual Mechanism Differs from Single GLP-1 Agonists. For the broader class context, see Tirzepatide and Body Composition: What Happens to Muscle?.
Key Takeaways
- SURMOUNT-1: Tirzepatide 15 mg produced 22.5% mean weight loss vs 2.4% for placebo over 72 weeks in 2,539 adults with obesity (Jastreboff et al., NEJM, 2022)[1]
- SURMOUNT-2: In adults with obesity AND type 2 diabetes, tirzepatide 15 mg achieved 14.7% weight loss vs 3.2% for placebo (Garvey et al., Lancet, 2023)[2]
- SURMOUNT-4: Stopping tirzepatide after 36 weeks caused 14% weight regain over the next year, while continuing treatment led to 5.5% additional loss (Aronne et al., JAMA, 2024)[4]
- SURMOUNT-5: In the first head-to-head trial, tirzepatide beat semaglutide with 20.2% vs 13.7% weight loss at 72 weeks (Aronne et al., NEJM, 2025)[5]
- Three-year data showed tirzepatide reduced type 2 diabetes risk by 94% in people with obesity and prediabetes (Jastreboff et al., NEJM, 2025)[6]
SURMOUNT-1: The Landmark Trial That Changed Everything
SURMOUNT-1 was the pivotal trial that established tirzepatide's weight loss credentials. Published in the New England Journal of Medicine in 2022, it enrolled 2,539 adults with a BMI of 30 or higher (or 27+ with at least one weight-related complication) but without diabetes.[1]
Participants were randomized 1:1:1:1 to receive once-weekly subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo for 72 weeks. The results at each dose:
| Dose | Mean Weight Loss | Participants Losing 5%+ | Participants Losing 20%+ |
|---|---|---|---|
| 5 mg | 15.0% (35 lb) | 85% | 32% |
| 10 mg | 19.5% (49 lb) | 89% | 50% |
| 15 mg | 20.9% (52 lb) | 91% | 57% |
| Placebo | 3.1% (5 lb) | 35% | 3% |
At baseline, the mean body weight was 104.8 kg (231 lb) and the mean BMI was 38.0. The 15 mg dose produced 52 pounds of weight loss on average, and more than half of participants at that dose lost over 20% of their body weight. No previous single-agent therapy had achieved these numbers in a phase 3 trial.[1]
Beyond weight, SURMOUNT-1 showed improvements across cardiometabolic markers including blood pressure, triglycerides, and waist circumference. Gastrointestinal side effects (nausea, diarrhea, constipation) were the most common adverse events, mostly mild to moderate and concentrated during the 20-week dose-escalation phase. Treatment discontinuation due to adverse events ranged from 4.3% to 7.1% across tirzepatide doses versus 2.6% for placebo.
A body composition sub-analysis published by Look et al. (2025) in Diabetes, Obesity & Metabolism found that on the 15 mg dose, total body weight decreased 21.3%, fat mass decreased 33.9%, and lean mass decreased 10.9%. The ratio was roughly 3:1 fat to lean mass loss, which is better than what bariatric surgery typically achieves but still means substantial muscle loss at higher weight reductions.[7]
SURMOUNT-2: Tirzepatide in People With Type 2 Diabetes
Weight loss peptide drugs consistently produce smaller reductions in people who also have type 2 diabetes, and SURMOUNT-2 confirmed this pattern for tirzepatide. Published in The Lancet in 2023, the trial enrolled 938 adults with both obesity (BMI 27+) and type 2 diabetes.[2]
At 72 weeks:
- 10 mg: 13.4% weight loss (vs 3.2% placebo)
- 15 mg: 14.7% weight loss (vs 3.2% placebo)
These numbers are lower than SURMOUNT-1's 19.5% and 20.9% at the same doses, confirming the consistent finding that insulin resistance and metabolic dysfunction blunt weight loss response. Still, 14.7% weight loss in a population with type 2 diabetes exceeded what any previous GLP-1 receptor agonist had achieved in this population.
SURMOUNT-2 also demonstrated substantial glycemic improvements: HbA1c decreased by 2.1 percentage points with tirzepatide 15 mg versus 0.5 points with placebo. Over 80% of participants on tirzepatide achieved an HbA1c below 7.0%, and many reached levels below 5.7% (the threshold for normal glucose tolerance).[2]
SURMOUNT-3: Adding Tirzepatide After Lifestyle Intervention
SURMOUNT-3 asked a practical clinical question: does tirzepatide add benefit for people who have already lost weight through intensive lifestyle intervention? Published in Nature Medicine in 2023, the trial first put all 579 participants through a 12-week intensive lifestyle program (low-calorie diet plus increased physical activity).[3]
Participants who achieved at least 5% weight loss during the run-in phase were then randomized to tirzepatide (maximum tolerated dose) or placebo for an additional 72 weeks.
The combined result: participants who received tirzepatide after intensive lifestyle intervention lost a total of 26.6% of their body weight from the original baseline. This was the highest total weight loss number across any SURMOUNT trial, demonstrating that lifestyle intervention and tirzepatide have additive effects.[3]
This matters for clinical practice because it validates a stepped approach: starting with lifestyle changes, then adding tirzepatide if weight loss goals are not met.
SURMOUNT-4: What Happens When You Stop Tirzepatide
SURMOUNT-4 addressed the question patients care about most after "how much weight will I lose?": what happens when I stop? Published in JAMA in January 2024, the trial had a unique design.[4]
All 670 participants received open-label tirzepatide (maximum tolerated dose) for 36 weeks. Those who achieved at least 5% weight loss were then randomized to continue tirzepatide or switch to placebo for another 52 weeks.
The results were unambiguous:
- Continue tirzepatide: Additional 5.5% weight loss (25.3% total from baseline)
- Switch to placebo: 14.0% weight regain (9.9% total loss from baseline)
From week 36 to 88, participants who switched to placebo regained an average of 14 percentage points, erasing much of the initial benefit. Those who continued tirzepatide kept losing. The divergence was visible across every metabolic marker: blood pressure, waist circumference, and lipid levels all worsened in the group that stopped treatment.[4]
SURMOUNT-4 established that tirzepatide works as long as you take it. Stopping treatment leads to predictable and substantial weight regain, matching the pattern seen with semaglutide discontinuation studies. This has implications for insurance coverage, treatment planning, and how obesity is conceptualized: as a chronic condition requiring ongoing management rather than a problem that can be "fixed" with a temporary course of medication. For how this pattern compares to semaglutide, see Semaglutide Weight Regain: What the Studies Show After Discontinuation.
SURMOUNT-5: Tirzepatide vs Semaglutide Head-to-Head
The trial the field had been waiting for. Published in the New England Journal of Medicine in May 2025, SURMOUNT-5 was the first direct head-to-head comparison between tirzepatide (Zepbound) and semaglutide (Wegovy) for obesity.[5]
The phase 3b, open-label trial randomized 751 adults with obesity (BMI 30+, no diabetes) 1:1 to receive the maximum tolerated dose of either tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg) once weekly for 72 weeks.
Results at 72 weeks:
- Tirzepatide: 20.2% weight loss
- Semaglutide: 13.7% weight loss
- Estimated treatment difference: 6.5 percentage points (p<0.001)
Tirzepatide also produced greater reductions in waist circumference (18.4 cm vs 13.0 cm). Gastrointestinal adverse events leading to discontinuation were more common with semaglutide (5.6%) than tirzepatide (2.7%).[5]
The open-label design is a limitation worth noting. Participants knew which drug they received, which could influence adherence, diet behavior, and subjective reporting of side effects. A double-blind comparison would be more definitive. Still, a 6.5 percentage point gap is large enough that blinding effects are unlikely to explain the entire difference.
For a deeper dive on how these two drugs compare beyond weight loss, see Tirzepatide vs Semaglutide: Which One Leads to More Weight Loss?.
Three-Year Data: Diabetes Prevention
The SURMOUNT-1 extension, published in the New England Journal of Medicine in late 2024, followed participants with both obesity and prediabetes for 176 weeks (3.4 years) of continuous tirzepatide treatment.[6]
Weight loss was sustained at three years:
- 5 mg: 12.3% weight loss
- 10 mg: 18.7% weight loss
- 15 mg: 19.7% weight loss
- Placebo: 1.3% weight loss
The diabetes prevention finding was remarkable: only 1.3% of tirzepatide-treated participants progressed to type 2 diabetes versus 13.3% on placebo. That translates to a 94% relative risk reduction (hazard ratio 0.07). Even after a 17-week washout period without treatment, the protection persisted: 2.4% of tirzepatide-treated participants versus 13.7% of placebo participants had diabetes.[6]
These are stronger diabetes prevention results than those seen with metformin or intensive lifestyle intervention in the landmark Diabetes Prevention Program, though direct comparison across different trials has limitations.
How Tirzepatide Produces These Results
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Unlike semaglutide (which targets GLP-1 receptors only), tirzepatide activates both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. The dual mechanism appears to produce effects beyond what GLP-1 alone achieves.
Heise et al. (2023) published data in Diabetes Care showing that tirzepatide reduced appetite, decreased energy intake, and preferentially reduced fat mass in people with type 2 diabetes. Participants on tirzepatide consumed fewer calories without being instructed to diet, and the caloric reduction was sustained over the treatment period.[8]
The GIP receptor component may explain tirzepatide's advantage over pure GLP-1 agonists. GIP receptors in adipose tissue and the central nervous system appear to enhance fat oxidation and appetite suppression through pathways that are additive to GLP-1 signaling. For a complete breakdown of this dual mechanism, see How Tirzepatide's Dual Mechanism Differs from Single GLP-1 Agonists.
What the SURMOUNT Data Does Not Tell Us
The SURMOUNT program answered the big questions about efficacy and short-term safety. Several gaps remain:
Long-term cardiovascular outcomes. The SELECT trial established semaglutide's cardiovascular benefit. No equivalent outcomes trial has reported for tirzepatide yet. The SURPASS-CVOT trial is ongoing but results are not expected until the late 2020s.
Durability beyond three years. SURMOUNT-1's extension provides 176 weeks of data. Whether weight loss plateaus, continues, or gradually reverses with longer treatment is unknown.
Population specificity. SURMOUNT-1 and SURMOUNT-5 excluded people with diabetes. SURMOUNT-2 included only people with type 2 diabetes. Data on type 1 diabetes, adolescents, and older adults (over 75) is limited.
Real-world adherence. Clinical trial participants receive regular monitoring, dose titration support, and free medication. Real-world adherence, where cost, side effects, and insurance barriers play larger roles, may produce different results.
For a practical look at dosing differences and their clinical significance, see Tirzepatide Dose Response: How Weight Loss Changes at Each Dose. For brand name differences, see Mounjaro vs Zepbound: Understanding Tirzepatide's Two Brand Names.
The Bottom Line
The SURMOUNT program established tirzepatide as the most effective single-agent weight loss medication tested in phase 3 trials, with 20-22.5% body weight reduction in people without diabetes and 14.7% in people with type 2 diabetes. SURMOUNT-5 demonstrated superiority over semaglutide in a direct comparison. SURMOUNT-4 confirmed that stopping treatment leads to substantial regain. Three-year data showed sustained weight loss and a 94% reduction in diabetes progression. Key unknowns remain: long-term cardiovascular outcomes, durability beyond three years, and real-world performance outside clinical trial conditions.